Location
Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, Colorado
Hotel Phone: (303) 436-1234
Program Schedule — Mountain Time
11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting
Meeting Room
Capitol Ballroom (Fourth Floor)
Faculty Rahul Aggarwal, MD
Professor of Medicine and Thomas Perkins Distinguished Professor of Cancer Research
Director, Genitourinary Medical Oncology
University of California, San Francisco
Department of Medicine
Division of Hematology/Oncology
Associate Director for Clinical Research
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Monica Averia, MSN, AOCNP, NP-C
Oncology Nurse Practitioner
Clinical Instructor of Medicine
USC Norris Cancer Center
Los Angeles, California
Kathleen D Burns, RN, MSN, AGACNP-BC, OCN
Genitourinary Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, California
William K Oh, MD
Director of Precision Medicine
Yale Cancer Center
Professor of Medicine Division of Medical Oncology
Yale School of Medicine
Medical Director, Service Line
Smilow Cancer Hospital at Greenwich Hospital
New Haven, Connecticut
Meeting space has been assigned to provide a satellite symposium supported by Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, and Novartis during the Oncology Nursing Society’s (ONS) 50th Annual Congress, April 9-13, 2025 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Mountain Time
11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting
Advances in the Treatment of Nonmetastatic Prostate Cancer
Rationale for the evaluation of treatment intensification with secondary hormonal agents combined with androgen deprivation therapy (ADT)
Key findings with enzalutamide alone and combined with leuprolide for men with nonmetastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence after definitive therapy
FDA approval and optimal application of enzalutamide with and without ADT in clinical practice
Other available datasets documenting the efficacy of androgen receptor pathway inhibitors for patients with nonmetastatic prostate cancer
Treatment Approaches for Metastatic HSPC (mHSPC)
Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for men with mHSPC
Key outcomes reported with the addition of darolutamide to ADT for patients with mHSPC; clinical implications
Published efficacy and safety data with darolutamide in combination with docetaxel and ADT for mHSPC; selection of optimal candidates for triplet therapy
Mechanism of action of capivasertib; emerging efficacy and safety results with capivasertib in combination with abiraterone/ADT for patients with de novo mHSPC and PTEN deficiency
Tolerability of Hormonal Therapy for Prostate Cancer
Tolerability profile of enzalutamide with and without ADT for nmHSPC; differences, if any, from the experience with this agent in later settings
Incidence of hypertension and other cardiovascular adverse events (AEs) with different hormonal agents; optimal pretreatment cardiovascular assessment and monitoring and management of side effects during therapy
Spectrum and frequency of CNS-related AEs, such as seizures, cognitive decline, falls and fatigue, observed with hormonal therapy for patients with prostate cancer
Prevalence of other notable side effects with available hormonal therapies for prostate cancer, such as fractures, hot flashes, sarcopenia and rash
Role of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Incidence of BRCA1/2 and other homologous recombination repair abnormalities in prostate cancer; indications for and optimal timing and practical implementation of genetic testing
Long-term findings with and indications for PARP inhibitor monotherapy for mCRPC
Biological basis for combining PARP inhibitors with secondary hormonal therapies for prostate cancer
Published findings with olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide as first-line therapy for patients with mCRPC
FDA-approved indications for olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide for mCRPC; optimal selection of patients for these approaches
Tolerability of PARP Inhibitors for Prostate Cancer
Incidence, timing and severity of common class-effect and agent-specific toxicities associated with PARP inhibitors for patients with mCRPC
Impact on the tolerability of PARP inhibitors when administered in combination with secondary hormonal therapy
Optimal monitoring and management approaches for PARP inhibitor-related toxicities
Strategies for identifying the root cause of toxicities in patients receiving PARP inhibitors or secondary hormonal therapy combinations that may be attributable to either agent
Utility of Radium-223 for Patients with mCRPC
Mechanism of antitumor activity of radium-223; rationale for its activity in bone metastases but not in other organs
Long-term findings with radium-223 monotherapy for mCRPC
Recently presented data with radium-223 and enzalutamide versus enzalutamide alone as first-line therapy for mCRPC with bone metastases
Patient selection for and optimal integration of radium-223 into mCRPC treatment algorithms; role, if any, in combination with other systemic therapies
Current and Future Role of PSMA-Targeted Radiopharmaceuticals in Therapy for mCRPC
Clinical relevance of PSMA expression in prostate cancer; mechanism of action of lutetium Lu 177 vipivotide tetraxetan
Published datasets with lutetium Lu 177 vipivotide tetraxetan for patients with chemotherapy-pretreated and chemotherapy-naïve, PSMA-positive mCRPC
Appropriate sequencing of lutetium Lu 177 vipivotide tetraxetan opposite other available therapies
Tolerability and Other Practical Considerations with Novel Radiopharmaceuticals for Prostate Cancer
Incidence, severity and management of commonly occurring AEs with radium-223, such as cytopenias, gastrointestinal (GI) toxicity, peripheral edema and fracture
Recommended algorithms for the management of common AEs observed in patients receiving lutetium Lu 177 vipivotide tetraxetan, such as fatigue, dry mouth, GI toxicity and cytopenias
Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
Evaluate the published research supporting the FDA approvals of secondary hormonal agents for nonmetastatic prostate cancer, including for patients with biochemical recurrence after local therapy, and apply this information in the discussion of nonresearch treatment options.
Understand how age, comorbidities, prior therapeutic exposure and other clinical and biological factors affect the selection and sequencing of available therapeutic options for patients with metastatic castration-resistant prostate cancer (mCRPC).
Understand how age, comorbidities, prior therapeutic exposure and other clinical and biological factors affect the selection and sequencing of available therapeutic options for patients with mCRPC.
Assess the available research supporting the use of PARP inhibitors as monotherapy or in combination with androgen receptor pathway inhibitors for patients with mCRPC harboring a homologous recombination repair gene alteration, and identify appropriate candidates for available agents and regimens.
Appreciate Phase III data documenting the efficacy of PSMA-targeted radioligand therapy for PSMA-positive mCRPC, and consider the current and future clinical role of this strategy.
Implement a plan of care to recognize and manage side effects and toxicities associated with approved therapies for prostate cancer.
Recall the design of ongoing clinical trials evaluating other novel therapies for prostate cancer, and counsel appropriate patients about availability and participation.
Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2025/ProstateCancer/ILNA
Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.
Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Ms Averia has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:
RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, and Novartis.
Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room
Capitol Ballroom (Fourth Floor)
The Hyatt Regency Denver at Colorado Convention Center is the headquarters hotel for the 2025 ONS Congress and is adjacent to the Colorado Convention Center.
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.
There is no registration fee for this event. For the in-person symposium in Denver, preregistration is required as seating is limited.
NOTICE: Registration for this event is independent of registration for the 2025 ONS Congress.
IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
